candesartan Side Effects
Also known as: Atacand
Analysis of 33,477 adverse event reports submitted to the FDA from 2004 to 2025.
Total Reports
33,477
Death-Related
4,308
12.9% of reports
Hospitalizations
17,659
52.7% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 4,308 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| OFF LABEL USE | 1,190 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 945 |
| CONDITION AGGRAVATED | 841 |
| INTENTIONAL PRODUCT USE ISSUE | 809 |
| ASTHENIA | 799 |
| MATERNAL EXPOSURE DURING PREGNANCY | 796 |
| PEMPHIGUS | 790 |
| FOLLICULITIS | 777 |
| SYSTEMIC LUPUS ERYTHEMATOSUS | 768 |
| TYPE 2 DIABETES MELLITUS | 766 |
| BURSITIS | 763 |
| PAIN | 763 |
| PERICARDITIS | 760 |
| GLOSSODYNIA | 758 |
| SYNOVITIS | 753 |
| HYPOAESTHESIA | 749 |
| HYPERTENSION | 747 |
| PNEUMONIA | 747 |
| DIARRHOEA | 745 |
| CONFUSIONAL STATE | 743 |
Reactions in Hospitalization Reports
Top reactions in 17,659 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| DYSPNOEA | 2,128 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 1,987 |
| NAUSEA | 1,835 |
| OFF LABEL USE | 1,835 |
| FATIGUE | 1,815 |
| DIARRHOEA | 1,677 |
| VOMITING | 1,620 |
| DIZZINESS | 1,586 |
| PAIN | 1,548 |
| ASTHENIA | 1,474 |
| PNEUMONIA | 1,423 |
| HEADACHE | 1,411 |
| FALL | 1,403 |
| CONDITION AGGRAVATED | 1,296 |
| HYPERTENSION | 1,260 |
| ACUTE KIDNEY INJURY | 1,240 |
| PYREXIA | 1,231 |
| DRUG INEFFECTIVE | 1,229 |
| MALAISE | 1,227 |
| ARTHRALGIA | 1,181 |
Nearby — Related Medications
What the FAERS Data Reveals About candesartan Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 33,477 voluntary reports linked to candesartan and its brand equivalents (Atacand), spanning 2004 through 2025. Of those, 4,308 (12.9%) listed death as an outcome and 17,659 (52.7%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 57% were female and 43% male; age distribution skews toward 75+, with 9,109 reports in that bracket. The single most reported reaction is off label use with 3,515 submissions, followed by dyspnoea and fatigue.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.